ADHD

Dr David W. Goodman reviews the efficacy and tolerability of different classes of medications for the management of ADHD.

Rakesh Jain, MD, MPH, explores the role of an integrative treatment approach in regard to nonpharmacological treatment for the management of adult ADHD.

Rakesh Jain, MD, MPH, leads a discussion on factors that guide treatment selection for adult patients with ADHD.

The digital software program was significantly beneficial and tolerable among patients who used it over 6 weeks, according to new findings.

Experts in ADHD discuss the benefits and challenges of telehealth on the diagnosis and management of adult ADHD.

Birgit H. Amann, MD, and Greg Mattingly, MD, review patient and provider goals of treatment and provide insight on evaluating response to treatment for ADHD.

Greg Mattingly, MD; David W. Goodman, MD; Birgit H. Amann, MD; and Theresa R. Cerulli, MD, evaluate the role of pediatric ADHD guidelines and common misconceptions in the diagnosis and treatment of ADHD.

Drs Birgit H. Amann, David W. Goodman, and Greg Mattingly discuss signs and symptoms that may prompt testing for adult ADHD and share their considerations for approaching diagnosis.

Experts in the management of ADHD comment on unmet needs in disease management in the areas of diagnosis, treatment, and coverage of symptoms.

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; David W. Goodman, MD; Greg Mattingly, MD; and Theresa R. Cerulli, MD, share insight on the impact of ADHD on quality of life in adult patients.

Drs David W. Goodman, Rakesh Jain, Greg Mattingly, and Theresa R. Cerulli, discuss continuation of ADHD from childhood as well as data on remission of ADHD in adulthood.

David W. Goodman, MD; Greg Mattingly, MD; and Birgit H. Amann, MD, provide an overview of ADHD, including its pathophysiology as well as its prevalence in the pediatric and adult populations.

Brain development could be impaired due to iron deficiencies, leading to an increased risk of ADHD.

Qbtech is hoping to address some gaps in testing and screening for the specific symptoms of ADHD in individuals aged 6-60.

Prior studies have predominantly considered the associations of respiratory allergy and skin allergy in patients with ADHD, with inconsistent data on food allergy.

A better understanding of this connection could yield preventative treatments.

Previous research have focused mostly on adults or patients with other comorbidities.

Participants with at least 3 psychiatric disorders more likely had a family history of psychiatric disorders.

Copy number variations were broadly associated with an increased risk of autism spectrum disorder and ADHD.

Few studies have focused on the psychosocial adjustments of siblings of children with ADHD.

In recent years there has been an expansion of trials in different methods of treatment settings, providers, countries, and delivery methods.

A combination of poor performance and methodological limitations were found for the machine learning models.

Dr. Glanzman presented during AAP 2021 about executive function impairments in patients with ADHD.

Students with ADHD have struggled with virtual schooling during the COVID-19 pandemic.

Executive function can include working memory, behavioral inhibition, and cognitive flexibility.

Dr. Chan said clinical practice guidelines ideally cover about 75% of patients with ADHD.

Children are now screened for autism at 18 and 24 months.

Immigrant children were less likely to be diagnosed with ADHD compared to children of US born parents.

The AAP guidelines for ADHD were first released in 2000 and last updated in 2019.

Dr. Carbone will present during AAP 2021 about managing autism in pediatric practices.